I3Y-MC-JPEH: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502269-13-00

Acronym

I3Y-MC-JPEH

Enrollment

Registered

2024-08-05

Start date

2024-09-24

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Brief summary

Event Free Survival as Determined by Blinded Independent Review Committee

Interventions

DRUGAbemaciclib

DRUGTEMOZOLOMIDE

DRUGVerzenios 50 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Event Free Survival as Determined by Blinded Independent Review Committee	—

Countries

Belgium, Denmark, France, Italy, Netherlands, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026